Patents by Inventor Simon PUTTICK

Simon PUTTICK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RADIOISOTOPE SOURCE
    Publication number: 20260237534
    Abstract: A layered radioisotope source for generating a medically useful dose of daughter radioisotope through a chain of spontaneous decay from a parent radioisotope via a gaseous intermediate radioisotope, comprising: an inert ceramic substrate layer; a metal oxide surface layer bound on the inert ceramic substrate layer; and parent radioisotope immobilised on or within the metal oxide surface layer to allow for effective emanation of the gaseous intermediate radioisotope away from the layered radioisotope source.
    Type: Application
    Filed: February 20, 2024
    Publication date: August 13, 2026
    Inventors: Nicolò CANEVER, Julian KELLY, Simon PUTTICK, William TIEU, Kevin KUAN
  • RADIOPHARMACEUTICALS
    Publication number: 20250352678
    Abstract: This application relates generally to prostate specific membrane antigen (PSMA) targeting compounds which may be complexed to a radioisotope. Pharmaceutical compositions including such compounds also disclosed. Such compounds or pharmaceutical compositions may be used in nuclear medicine for the in-vivo imaging of various tissues, and the treatment and/or prevention of various PSMA-expressing cancers, especially prostate cancer.
    Type: Application
    Filed: July 24, 2025
    Publication date: November 20, 2025
    Inventors: Simon PUTTICK, William TIEU, Kevin KUAN
  • Radiopharmaceuticals
    Patent number: 12419977
    Abstract: This application relates generally to prostate specific membrane antigen (PSMA) targeting compounds which may be complexed to a radioisotope. Pharmaceutical compositions including such compounds also disclosed. Such compounds or pharmaceutical compositions may be used in nuclear medicine for the in-vivo imaging of various tissues, and the treatment and/or prevention of various PSMA-expressing cancers, especially prostate cancer.
    Type: Grant
    Filed: November 14, 2024
    Date of Patent: September 23, 2025
    Assignee: AdvanCell Isotopes Pty Limited
    Inventors: Simon Puttick, William Tieu, Kevin Kuan
  • RADIOPHARMACEUTICALS
    Publication number: 20250064994
    Abstract: This application relates generally to prostate specific membrane antigen (PSMA) targeting compounds which may be complexed to a radioisotope. Pharmaceutical compositions including such compounds also disclosed. Such compounds or pharmaceutical compositions may be used in nuclear medicine for the in-vivo imaging of various tissues, and the treatment and/or prevention of various PSMA-expressing cancers, especially prostate cancer.
    Type: Application
    Filed: November 14, 2024
    Publication date: February 27, 2025
    Inventors: Simon PUTTICK, William TIEU, Kevin KUAN
  • BINDING PROTEINS TO CUB DOMAIN-CONTAINING PROTEIN (CDCP1)
    Publication number: 20220389113
    Abstract: The present disclosure relates to anti-CDCP1 antibodies, and antigen binding fragments thereof that specifically bind to the full length and cleaved forms CUB domain-containing protein 1 (CDCP1), and conjugates comprising anti-CDCP1 antibodies and uses thereof for treatment and detection of cancer.
    Type: Application
    Filed: November 6, 2020
    Publication date: December 8, 2022
    Inventors: Simon PUTTICK, Thomas KRYZA, John HOOPER, Yaowu HE, Brittney HARRINGTON, James QUIGLEY, Elena DERYUGINA